Hybio Pharmaceutical Co Ltd

300199
stockHealthcarePharmaceuticals
$6/day into 300199 since 2015 would be worth $33,802 today — 2.0× the money.
Try your own number →

Hybio Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of peptide and oligonucleotide drugs in China and internationally. The company offers finished dosage form (FDF) products for obstetrics and gynecology, haemostatic agent, digestive tract and metabolic systems, immune system modulation, cardiovascular, diabetes mellitus, and osteoporosis, as well as disposable injectable pens; and peptide active pharmaceutical ingredients (API) comprising polypeptides, small molecules and nucleic acids, and intermediates for endocrine, nutritional, and metabolic diseases; digestive system diseases; neoplasms; nervous system diseases; pregnancy, childbirth, and puerperium; musculoskeletal system and connective tissue diseases; infectious and parasitic diseases; circulatory system diseases; blood and hematopoietic organ diseases; and genitourinary system diseases, as well as factors influencing health status. It also provides contract research, development, and manufacturing organization (CRDMO) services for peptide APIs, peptide formulations, oligonucleotide drugs, and pharmaceutical intermediates. In addition, the company engages in the provision of property services. Hybio Pharmaceutical Co., Ltd. was founded in 1998 and is headquartered in Wuhan, China.

Description from Yahoo Finance
Full profile on Yahoo Finance →

If you'd bought from year…

Same habit, different start year. Each row shows what a constant habit's worth of 300199-SZ would be worth today, had you started buying at that point in the asset's history.

Started$6/day$6/day coffee$42/wk$42/week coffee
Year 1 (2011) — listing
$56,402
2.6×
$83,212
2.6×
Year 6 (2016)
$32,286
2.1×
$47,633
2.1×
Year 11 (2021)
$16,671
2.1×
$24,769
2.1×

Repeated investment, no fees, dividends reinvested. $6/day coffee = $180 / month equivalent.

Popular scenarios with 300199

For illustration only — not investment advice. Past performance is not indicative of future results.